NEW YORK (GenomeWeb News) – DiaGenic today said that it has licensed biomarkers for mild cognitive impairment to drug firm Merz Pharmaceuticals, which will use the biomarkers for recruiting patients for Alzheimer's disease drug trials.

Frankfurt am Main, Germany-based Merz also has an option to license non-exclusive rights to further biomarkers, under terms of the agreement. Financial details and further terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.